Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RG-125
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
RG-125 (AZD4076) is a GalNAc-conjugated antisense oligonucleotide therapeutic targeting microRNA-103 and microRNA-107 (miR-103/107). It is designed to inhibit these specific microRNAs, which are implicated in the development of insulin resistance and metabolic dysfunction. By inhibiting miR-103/107, RG-125 aims to improve insulin sensitivity and glucose tolerance. The drug was developed for the treatment of non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes or pre-diabetes. The compound was selected as a clinical candidate by AstraZeneca from an alliance with Regulus Therapeutics[1][4][7][8]. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and effects on liver fat content and insulin sensitivity in subjects with type 2 diabetes mellitus and non-alcoholic fatty liver disease[2][5].
- Other names
- AZD4076AZD-4076AZD 4076
Beyond the preview
Go deeper on RG-125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RG-125.